BENDAFOLIN 10 mg/ml Injektionslösung
Sponsors
Transthera Sciences (Nanjing) Inc., Janssen - Cilag International, AstraZeneca AB, Enliven Therapeutics Inc., 1globe Health Institute LLC
Conditions
26.0)Advanced or Metastatic Colorectal CancerBiliary Tract CancerCholangiocarcinoma (LTTColorectal Cancer and Breast CancerGastric CancerGastroesophageal Junction CancerHistologically confirmed adenocarcinoma of the colon or rectum that is metastatic.
Phase 1
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer
RecruitingCTIS2023-506517-22-00
Start: 2022-08-31Target: 37Updated: 2025-12-12
A Phase 1a/1b Study of ELVN-002 Combined with Trastuzumab in Advanced Stage HER2+ Solid tumors, and ELVN-002 Combined with Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
Active, not recruitingCTIS2023-509716-29-00
Start: 2024-09-23Target: 156Updated: 2025-11-24
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)
RecruitingCTIS2023-508275-37-00
Start: 2024-11-11Target: 9Updated: 2026-01-14
A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in combination with Standard of Care (SoC) or other agents in Participants with Advanced Solid Tumors
RecruitingCTIS2025-522274-37-00
Start: 2025-12-03Target: 15Updated: 2025-11-21
Phase 3
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
RecruitingCTIS2023-505660-11-00
Start: 2024-04-24Target: 95Updated: 2026-01-26
A Phase III, Randomized, Open-Label Clinical Study of Napabucasin in Combination with FOLFIRI and Best Supportive Care (BSC) Versus Napabucasin plus BSC in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Active, not recruitingCTIS2024-518204-50-00
Start: 2022-04-25Target: 123Updated: 2025-12-10